🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Challenge

Gonorrhoea infections are escalating globally, with estimates suggesting more than 82 million new cases each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

One new antibiotic, marketed under the name Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Outcomes and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which combines two antibiotics. The trial included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians treating patients have expressed optimism. Having a one-pill regimen of this kind is hailed as a "critical tool" for public health efforts. This is considered crucial to reduce the burden of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.